WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A.:
- Do you own shares of Cascadian Therapeutics, Inc. (NASDAQ GS: CASC)?
- Did you purchase any of your shares prior to January 31, 2018?
- Do you think the proposed buyout is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cascadian Therapeutics, Inc. (“Cascadian Therapeutics” or the “Company”) (NASDAQ GS: CASC) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Seattle Genetics, Inc. (“Seattle Genetics”) (NASDAQ GS: SGEN) in a transaction valued at approximately $614 million. Under the terms of the agreement, shareholders of Cascadian Therapeutics will receive $10.00 in cash for each share of Cascadian Therapeutics common stock.
If you own common stock of Cascadian Therapeutics and purchased any shares before January 31, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.